---
figid: PMC3846530__bctt-2-079Fig1
figlink: /pmc/articles/PMC3846530/figure/f1-bctt-2-079/
number: F1
caption: Mechanism of action of lapatinib. ERBB2 homodimerization or heterodimerization
  with other family members is promoted by binding of ligand (such as epithelial growth
  factor), and possibly by high receptor density secondary to ERBB2 amplification.
  Two key signaling pathways activated by receptor dimerization and activation are
  the Pi3K-Akt pathway, which promotes both cell survival and cell cycle progression,
  and the mitogen-activated protein kinase (MAPK) pathway, which stimulates proliferation.
  Lapatinib blocks the catalytic cleft of the ERBB1 and ERBB2 receptors, thereby preventing
  adenosine triphosphate binding and subsequent receptor phosphorylation leading to
  inhibition of downstream mitogenic signaling cascades.
pmcid: PMC3846530
papertitle: 'Lapatinib: new opportunities for management of breast cancer.'
reftext: Julia Liao, et al. Breast Cancer (Dove Med Press). 2010;2:79-91.
pmc_ranked_result_index: '8204'
pathway_score: 0.9656217
filename: bctt-2-079Fig1.jpg
figtitle: Mechanism of action of lapatinib
year: '2010'
organisms: Homo sapiens
ndex: ac4eadfb-ded1-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3846530__bctt-2-079Fig1.html
  '@type': Dataset
  description: Mechanism of action of lapatinib. ERBB2 homodimerization or heterodimerization
    with other family members is promoted by binding of ligand (such as epithelial
    growth factor), and possibly by high receptor density secondary to ERBB2 amplification.
    Two key signaling pathways activated by receptor dimerization and activation are
    the Pi3K-Akt pathway, which promotes both cell survival and cell cycle progression,
    and the mitogen-activated protein kinase (MAPK) pathway, which stimulates proliferation.
    Lapatinib blocks the catalytic cleft of the ERBB1 and ERBB2 receptors, thereby
    preventing adenosine triphosphate binding and subsequent receptor phosphorylation
    leading to inhibition of downstream mitogenic signaling cascades.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK8
  - MAPK3
  - SHC2
  - ARAF
  - GRB2
  - MAPK11
  - MAPK1
  - SHC3
  - BRAF
  - HRAS
  - SHC4
  - AKT3
  - AKT1
  - AKT2
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3CB
  - SOS2
  - KRAS
  - NRAS
  - RAF1
  - PIK3R4
  - SOS1
  - MAPK14
  - MAPK12
  - SHC1
  - PIK3R5
  - PIK3CA
  - MAPK9
  - MAPK10
  - MAPK13
  - PIK3R6
  - Cancer
  - Noonan syndrome
genes:
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC2
  entrez: '25759'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC3
  entrez: '53358'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC4
  entrez: '399694'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Sos
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: Shc
  symbol: SHC
  source: bioentities_symbol
  hgnc_symbol: SHC1
  entrez: '6464'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3846530__F1
redirect_from: /figures/PMC3846530__F1
figtype: Figure
---
